Rothera Mark 4
4 · Viracta Therapeutics, Inc. · Filed Dec 4, 2023
Insider Transaction Report
Form 4
Rothera Mark
DirectorPresident and CEO
Transactions
- Purchase
Common Stock
2023-11-30$0.49/sh+52,094$25,734→ 52,094 total - Purchase
Common Stock
2023-12-01$0.49/sh+47,906$23,627→ 100,000 total
Footnotes (2)
- [F1]Represents the weighted average share price of an aggregate total of 52,094 shares purchased in the price range of $0.48 to $0.51 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Represents the weighted average share price of an aggregate total of 47,906 shares purchased in the price range of $0.4750 to $0.5130 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.